TITLE

BOOP associated with nitrofurantoin

AUTHOR(S)
Fawcett, I. W.; Ibrahim, N. B. N.
PUB. DATE
February 2001
SOURCE
Thorax;Feb2001, Vol. 56 Issue 2, p161
SOURCE TYPE
Academic Journal
DOC. TYPE
Letter
ABSTRACT
Presents letters to the editor related to lung diseases, published in the February 2001 issue of the journal "Thorax."Discussion on a case stimulating the one involving the treatment of bronchitis patients with corticosteroids; Critique on researcher Neil Barnes' review of appropriate outcome measures in asthma.
ACCESSION #
12915382

 

Related Articles

  • Sex, Chronic Conditions Are Risk Factors in Patients With AAT Deficiency.  // Pulmonary Reviews;Oct2007, Vol. 12 Issue 10, p49 

    The article discusses research being done on the determinants of airflow obstruction in severe alpha-1-anti-trypsin deficiency. It references a study by Dawn L. DeMeo and colleagues published in the September 2007 issue of "Thorax." The study found that the markers of increased risk for severe...

  • INTRODUCTION. Mitchell, D. M.; Shaheen, S. O.; Woodcock, A. A. // Thorax;Oct2002 Supplement 2, Vol. 57, pii1 

    The article provides an introduction about the articles that are published in the October 2002 issue of the journal "Thorax." The collection of articles covers wide range of topics starting with the problems of investigating pulmonary infection in the immunocompromised patient and advances in...

  • Effect of therapeutic doses of mometasone furoate on cortisol levels in children with mild asthma. Skoner, David P.; Gentile, Deborah A.; Angelini, Betty // Allergy & Asthma Proceedings;Jan/Feb2010, Vol. 31 Issue 1, p10 

    Corticosteroids are the foundation of pharmacologic treatment for children with asthma. However, high-dose inhaled corticosteroid treatment can cause hypothalamic-pituitary-adrenal (HPA) axis suppression. We investigated the effect of three doses of mometasone furoate administered via dry-powder...

  • How Much Did Biases in the Study of Chronic Obstructive Pulmonary Disease Medications and Mortality Affect the Outcome? Gross, Nicholas J. // Annals of Internal Medicine;3/17/2009, Vol. 150 Issue 6, p425 

    Three letters to the editor are presented in response to the article by Todd A. Lee and colleagues on the impact of ipratropium on the risk for cardiovascular death and the impact of inhaled corticosteroids (ICSs) on the mortality of patients with chronic obstructive pulmonary disease (COPD).

  • Asthma biology.  // Thorax;Dec2003 Supplement 3, Vol. 58, piii60 

    Fixed airflow obstruction occurs in a minority of patients with asthma and is associated with increased morbidity and mortality. To identify potential risk factors for the development of fixed airflow obstruction, researchers have investigated the association between post bronchodilator FEV and...

  • When can personal best peak flow be determined for asthma action plans? Reddel, H. K.; Marks, G. B.; Jenkins, C. R. // Thorax;Nov2004, Vol. 59 Issue 11, p922 

    Background: Written asthma action plans based on personal best peak expiratory flow (PEF) consistently improve health outcomes, whereas those based on predicted PEF do not. Guidelines state that personal best PEF should be assessed over 2-3 weeks during good asthma control, but it is unclear how...

  • Use of inhaled corticosteroids following discharge From an emergency department for an acute exacerbation of asthma. Blais, L.; Beauchesne, M.-F. // Thorax;Nov2004, Vol. 59 Issue 11, p943 

    Background: Most patients who have an asthma exacerbation leading to a visit to an emergency department (ED) will benefit from treatment with inhaled corticosteroids (ICS) at discharge. We investigated whether asthmatic children and adolescents were receiving ICS after discharge from the ED and...

  • Asthma: clinical assessment.  // Thorax;Dec2004 Supplement, Vol. 59, p50 

    The article presents some papers related to clinical assessment of asthma. There is currently great interest in developing non-invasive measures of airway inflammation in asthma. Proposed markers of airway inflammation and or oxidative stress in asthma include the exhaled gases, nitric oxide...

  • Treatment Comparison of Budesonide/ Formoterol with Salmeterol/Fluticasone Propionate in Adults Aged ≥16 Years with Asthma: Post Hoc Analysis of a Randomized, Double-Blind Study. Kuna, Piotr // Clinical Drug Investigation;2010, Vol. 30 Issue 9, p565 

    Background: Three fixed maintenance-dose inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) combinations for the treatment of asthma are currently available: salmeterol/fluticasone propionate (Seretide™/Advair™/ Adoair™) budesonide/formoterol (Symbicort®) and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics